Recent Updates
Recently added Catalysts
MGNX Negative Sentiment Score: 25/100

MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: A class action lawsuit has been filed against MacroGenics, Inc. on behalf of investors who purchased the company's stock between March 7 and May 9, 2024. The lawsuit claims that MacroGenics made misleading statements regarding safety data from its TAMARACK Phase 2 study for the prostate cancer drug vobramitamab duocarmazine. Investors wishing to participate must do so by September 24, 2024, with no fees required upfront as all representation is handled on a contingency basis.

Market Sentiment Analysis

CONCERNS & RISKS

  • Shareholder filed a class action lawsuit against MacroGenics.
  • Allegations include misrepresentations related to safety data.
  • The lawsuit involves investors who purchased stock in a defined class period.

Full Press Release Details

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased the stock or sold puts of MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”).
For more information, submit a form at MacroGenics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, MacroGenics made misrepresentations related to early interim safety data results from the company’s TAMARACK Phase 2 study of a prostate cancer drug called vobramitamab duocarmazine.
If you wish to serve as lead plaintiff for the Class, you must file papers by September 24, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the MacroGenics class action lawsuit about?

The lawsuit alleges MacroGenics misrepresented safety data from its TAMARACK Phase 2 study.

Who can serve as lead plaintiff in the lawsuit?

Investors wishing to be lead plaintiff must file by September 24, 2024.

Are there any fees for shareholders participating in the lawsuit?

No, representation is on a contingency fee basis; shareholders incur no costs.

How can investors get more information about the lawsuit?

Investors can fill out a form or contact Investor Relations Manager Peter Allocco.

What is the class period for the lawsuit?

The class period for the lawsuit is from March 7, 2024, to May 9, 2024.

Last updated: Jul 29, 2024